Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02943590 · ClinicalTrials.gov registry record · Phase 2
STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)
A Phase 2 study of Heart Failure, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 4
- Study locations
NCT02943590: Completed Phase 2 study of Heart Failure, sponsored by Massachusetts General Hospital.
NCT02943590 is a Phase 2 study of Heart Failure that has completed, run by Massachusetts General Hospital. The registered enrollment target is 300 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02943590, a Phase 2 study of Heart Failure, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study will test whether atorvastatin, a drug commonly prescribed for reducing cholesterol levels, can protect the heart during chemotherapy with doxorubicin. Atorvastatin is from a family of medications that are commonly called "statins"
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Atorvastatin
Study Locations (4)
Massachusetts
- Massachusetts general Hospital - Boston
- Dana Farber Cancer Institute - Boston
Pennsylvania
- University of Pennsylvania Medical System - Philadelphia
Other
- McGill University Health Center - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2017-01-13 |
| Est. Completion | 2023-10-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02943590
The ClinicalTrials.gov registry entry for NCT02943590 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (85% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02943590 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Pennsylvania, Other.
Frequently Asked Questions
What is clinical trial NCT02943590 about?
NCT02943590 is a clinical study titled "STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)". This research study will test whether atorvastatin, a drug commonly prescribed for reducing cholesterol levels, can protect the heart during chemotherapy with doxorubicin. Atorvastatin is from a family of medications that are commonly called "statins"
What is the current status of trial NCT02943590?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2017-01-13. Estimated completion is 2023-10-11.
What conditions does trial NCT02943590 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT02943590?
The interventions under investigation include: Placebo (DRUG), Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT02943590?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02943590 being conducted?
This trial has 4 study locations across Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
RECRUITING · Phase 2
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 2
-
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
-
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.